Publications by authors named "J A Ressler"
The development of keratinocytic skin tumors, presumably attributable to paradoxical activation of the MAPK pathway, represents a relevant side effect of targeted therapies with BRAF inhibitors (BRAFis). The role of cutaneous papillomavirus infection in BRAFi-associated skin carcinogenesis, however, is still inconclusive. Employing the Mus musculus papillomavirus 1 (MmuPV1) skin infection model, the impact of BRAFis and UVB exposure on papillomavirus induced skin tumorigenesis was investigated in immunocompetent FVB/NCrl mice.
View Article and Find Full Text PDFTargeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects.
View Article and Find Full Text PDFPurpose: The objective of this study was to evaluate whether uptake on F-fluorodeoxyglucose (F-FDG) PET could help differentiate HER2-positive from HER2-negative breast cancer brain metastases.
Methods: In this retrospective, cross-sectional study of a cohort of 14 histologically proven breast cancer brain metastases, we analyzed both preoperative F-FDG PET/CT and HER2 status of the resected/biopsied brain specimens. The maximum standardized uptake values (SUVmax) of the lesions were normalized to contralateral normal white matter and compared using Mann-Whitney tests.
Article Synopsis
- Treatment with monoclonal antibodies ixekizumab (anti-IL-17A) and adalimumab (anti-TNFα) is effective for managing chronic plaque psoriasis, but their impact on immune cell populations in the skin remains unclear.
- The study found that both treatments successfully reduced the levels of T cells, macrophages, and dendritic cells in the affected skin, aligning them more closely with healthy skin levels.
- However, neither treatment was able to correct the imbalance of dendritic cells in non-lesional skin of psoriatic patients, indicating that while the therapies help with lesions, they do not fully restore immune balance in unaffected areas.